Company Summary - Inke Rebirth (SH 688087) announced a share buyback of approximately 1.42 million shares, accounting for 0.73% of the total share capital, with a total expenditure of approximately RMB 39.92 million [1] - The highest and lowest prices for the buyback were RMB 30.39 and RMB 25.43 per share, respectively [1] - As of the report, Inke Rebirth has a market capitalization of RMB 5.7 billion [1] Industry Summary - The industry is experiencing a significant increase in overseas orders, with a reported growth of 246%, covering over 50 countries and regions [1] - Entrepreneurs have raised concerns about some companies selling at a loss, warning of potential vicious competition expanding into overseas markets [1]

Listing Overview - Suzhou Fengbei Biotechnology Co., Ltd. will be listed on the Shanghai Stock Exchange on November 5, 2025, with a total share capital of 143.5 million shares, of which 35.9 million shares are newly issued [1][4]. Initial Public Offering (IPO) Details - The IPO price is set at 24.49 CNY per share, corresponding to a price-to-earnings (P/E) ratio of 21.28 times based on the 2024 earnings before non-recurring gains and losses [4]. - The total number of shares available for public trading after the IPO will be 31.05 million shares, accounting for 21.64% of the total share capital [3][4]. Market Comparisons - The average static P/E ratio for the waste resource comprehensive utilization industry is reported at 64.73 times as of October 22, 2025 [5]. - The diluted P/E ratio of the company at the IPO price is 30.47 times, which is lower than the industry average and comparable companies' average P/E ratios [6]. Trading Risks - The first five trading days will have no price fluctuation limits, which may lead to significant price volatility [2]. - The limited number of circulating shares may pose liquidity risks in the initial trading period [3]. Contact Information - The company is located at Jiangsu Yangtze River International Chemical Industrial Park, and the contact number is 0512-58329931 [8]. - The lead underwriter is Guotai Junan Securities Co., Ltd., located in Shanghai, with a contact number of 021-38032666 [9].

股票简称：丰倍生物 股票代码：603334 苏州丰倍生物科技股份有限公司 SUZHOU FENGBEI BIOTECH STOCK CO., LTD. （江苏扬子江国际化学工业园东海路 1 号） 首次公开发行股票主板上市公告书 保荐人（主承销商） （中国（上海）自由贸易试验区商城路 618 号） 二〇二五年十一月四日 苏州丰倍生物科技股份有限公司 上市公告书 特别提示 苏州丰倍生物科技股份有限公司（以下简称"丰倍生物""发行人""本公 司"或"公司"）股票将于 2025 年 11 月 5 日在上海证券交易所主板上市。 本公司提醒投资者应充分了解股票市场风险及本公司披露的风险因素，在新 股上市初期切忌盲目跟风"炒新"，应当审慎决策、理性投资。 本上市公告书中若出现总数与各分项数值之和尾数不等的情况，均为四舍五 入尾差所致。 1 苏州丰倍生物科技股份有限公司 上市公告书 第一节 重要声明与提示 一、重要声明与提示 本公司及全体董事、监事、高级管理人员保证上市公告书所披露信息的真实、 准确、完整，承诺上市公告书不存在虚假记载、误导性陈述或者重大遗漏，并依 法承担法律责任。 上海证券交易所、有关政府机关对本公司股票上 ...

苏州丰倍生物科技股份有限公司 保荐人（主承销商）：国泰海通证券股份有限公司 扫描二维码查阅公告全文 本公司及全体董事、高级管理人员保证信息披露的内容真实、准确、完整、 及时，没有虚假记载、误导性陈述或重大遗漏。 经上海证券交易所（以下简称"上交所"）审核同意，苏州丰倍生物科技股 份有限公司（以下简称"丰倍生物""发行人"或"公司"）人民币普通股股票 将于 2025 年 11 月 5 日在上交所主板上市，上市公告书全文和首次公开发行股票 的招股说明书全文披露于上交所网站（http://www.sse.com.cn）和符合中国证券监 督管理委员会规定条件的网站（中国证券网，网址 www.cnstock.com；中证网， 网址 www.cs.com.cn；证券时报网，网址 www.stcn.com；证券日报网，网址 www.zqrb.cn； 经 济 参 考 网 ， 网 址 www.jjckb.cn； 金 融 时 报 ， 网 址 www.financialnews.com.cn；中国日报，网址 www.chinadaily.com.cn），并置备于 发行人、本次发行保荐人（主承销商）国泰海通证券股份有限公司的住所，供 ...

Group 1: New Stock Performance - Two new stocks were listed last week (October 20-24), with an average first-day price increase of 263.20%[2] - Both new stocks had first-day gains exceeding 100%, specifically Chao Ying Electronics at 397.60% and Marco Polo at 128.80%[2][4] - The total fundraising amount for new stocks last week increased by 1.591 billion yuan compared to the previous week[3] Group 2: Weekly and Monthly Trends - The number of new stocks listed remained unchanged at 2 for the week of October 20-24, with no first-day price drops recorded[3] - For the week of October 13-17, the average first-day price increase was 325.18%, with two stocks showing gains over 100%[4] - Monthly data shows that from October 1 to October 24, 5 new stocks were listed, raising 3.653 billion yuan, with an average first-day increase of 305.31%[10]

Group 1 - The company, Suzhou Fengbei Biotechnology Co., Ltd., is a high-tech enterprise in the field of waste resource utilization, primarily producing resource-based products from waste oils [2] - The controlling shareholder and actual controller of the company is Pingyuan, who directly holds 59.78% of the shares and indirectly controls an additional 25.62% through other entities, totaling 85.40% [2] - The company plans to raise 750 million yuan for projects including the production of 300,000 tons of oleic acid methyl ester and 50,000 tons of bio-diesel, among others [2] Group 2 - The company is set to issue shares at a price of 24.49 yuan per share, with an expected total fundraising amount of approximately 879.19 million yuan [2] - After deducting issuance costs of about 84.75 million yuan, the net fundraising amount is projected to be around 794.44 million yuan [2] - The issuance will include 35.9 million shares, with 11.49 million shares available for online subscription and 20.33 million shares for offline allocation [1]

Core Viewpoint - The company aims to become a leading enterprise in the global oil fat resource comprehensive utilization industry, focusing on three main directions: basic research, material development, and application development [1][2]. Business Overview - The company's main business is the comprehensive utilization of waste oil resources, primarily producing resource-based products from waste oils, with oil fat chemical products as a supplementary business [1][2]. - The company has developed a production chain of "waste oil - biofuels (biodiesel) - bio-based materials" and provides oil fat chemical products to customers based on its core technology and channel advantages [1][2]. Financial Performance - The sales revenue from the waste oil resource comprehensive utilization business has shown rapid growth, with revenues of 1.36 billion, 1.41 billion, 1.59 billion, and 1.35 billion yuan for the years 2022 to 2025, accounting for 79.53%, 81.94%, 81.68%, and 91.33% of the main business income respectively [3]. - The company's total operating income for the reporting period was 1.71 billion, 1.73 billion, 1.95 billion, and 1.48 billion yuan, with a year-on-year growth of 49.62% in the first half of 2025 [9]. Research and Development - The company has invested in R&D, with expenses of 51.35 million, 58.57 million, 53.57 million, and 34.45 million yuan over the reporting period, representing 3.00%, 3.39%, 2.75%, and 2.74% of operating income respectively [10]. - As of June 30, 2025, the company has obtained 135 patents, including 33 domestic invention patents and 3 international invention patents [4]. Development Strategy - The company aims to enhance its technology level and expand the application of bio-based materials, while also increasing production capacity and stabilizing procurement channels [11][12]. - Future plans include exploring biodiesel applications in aviation and shipping, and enhancing the supply chain layout with upstream food processing enterprises [11][12][13]. Industry Position - The company is positioned in the waste resource comprehensive utilization industry, specifically in the processing of non-metal waste [18]. - The industry is supported by national policies encouraging the comprehensive utilization of waste oils, with significant potential for growth due to the increasing production of waste oils from the food service sector [20]. Market Share - The company is among the top tier in the domestic waste oil resource comprehensive utilization industry, with a biodiesel production capacity of 105,000 tons, ranking sixth in China's biodiesel industry [24]. - The company's biodiesel production accounts for approximately 4.68% of the national biodiesel output, which is projected to be around 1.71 million tons in 2024 [24]. Fundraising and Investment - The total amount of funds raised will be used for projects related to the company's main business, including the construction of new production facilities for various bio-based products [25][26]. - The implementation of these projects is expected to expand market share and enhance profitability [26][28].

Company Overview - Yitong New Materials (SZ 300930) announced on October 24 that its third board meeting was held in Hangzhou, Zhejiang, discussing the revision of the "Board Secretary Work Rules" [1] - As of the report, Yitong New Materials has a market capitalization of 3.1 billion yuan [1] Financial Performance - For the first half of 2025, the revenue composition of Yitong New Materials is as follows: 83.02% from waste resource comprehensive utilization, 16.91% from forged and powder metallurgy products manufacturing, and 0.07% from other businesses [1]

Core Viewpoint - The report highlights the growth in the waste resource recycling industry in China, indicating an increase in the number of enterprises and their significance within the industrial sector [1]. Industry Summary - As of January to August 2025, the number of enterprises in the waste resource comprehensive utilization industry reached 4,127, which is an increase of 387 enterprises compared to the same period last year, representing a year-on-year growth of 10.35% [1]. - The proportion of these enterprises within the total industrial enterprises stands at 0.79% [1]. Company Summary - The report mentions several listed companies involved in the waste resource recycling sector, including Greenme (002340), Huicheng Environmental Protection (300779), Shenwu Energy Saving (000820), and others [1].

Group 1 - Investment Rating: The report assigns an AHP score of 2.61, placing the company in the 35.5% percentile of the non-Science and Technology Innovation Board AHP model [3][8][9] - Core Business: The company is a leading enterprise in the resource utilization of waste cooking oil, with a full industry chain layout from "waste cooking oil - biofuels - bio-based materials" [3][10] - Market Position: The company has a market share of approximately 6%-7% in the agricultural chemical sector, with bio-based materials accounting for 80% of its revenue [3][10] Group 2 - Industry Growth: The European Union is set to mandate large-scale blending of Sustainable Aviation Fuel (SAF) starting in 2025, creating significant market opportunities for the company [3][15] - Production Capacity: The company achieved a sales volume of 90,300 tons of industrial mixed oil in the first half of 2025, a year-on-year increase of 473.46% [3][18] - Financial Performance: The company reported a revenue of 1.478 billion yuan in the first half of 2025, a 50% increase year-on-year, with a projected revenue of 2.1 to 2.3 billion yuan for the first nine months of 2025 [20][21] Group 3 - Competitive Analysis: The average price-to-earnings ratio (TTM) for comparable companies is 31.09X, while the company's industry has a static P/E ratio of 64.44X [19] - Profitability Trends: The company's gross profit margin has declined from 13.55% in 2022 to 9.50% in the first half of 2025, primarily due to the lower value-added nature of industrial mixed oil products [24] - R&D Investment: The ratio of R&D expenditure to revenue has shown a downward trend, decreasing from 3.00% in 2022 to 2.33% in the first half of 2025 [30][33] Group 4 - Fundraising Plans: The company plans to raise 750 million yuan through the issuance of 35.9 million new shares, with funds allocated for expanding production capacity in various bio-based products [32][34] - Projected Returns: The internal rate of return for the new projects is estimated at 20.25%, with a payback period of approximately 6.83 years [35]